{
  "study_id": "NCT00373425",
  "study_title": "Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial",
  "table_name": "Table 1",
  "table_title": "Summary of Demographic and Baseline Characteristics (ITT population and EGFRm+ subgroup)",
  "description": "This table provides a summary of the demographic and baseline characteristics for two patient populations: the Intent-to-Treat (ITT) population and the subgroup of patients with EGFRm+ tumors.",
  "footnotes": [
    "NOTE. All randomly assigned patients (ITT population).",
    "Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFRm+, epidermal growth factor receptor-activating mutation; ITT, intent to treat; NSCLC, non-small-cell lung cancer; SD, standard deviation.",
    "*Western Europe included Austria, Belgium, France, Germany, Greece, Italy, Spain, and the United Kingdom.",
    "†Eastern Europe included the Czech Republic, Hungary, Poland, Romania, and Russia.",
    "‡The categories for EGFR mutation status were defined as follows: activating mutation positive, exon 19 deletion or exon 21 L858R (or both) was detected; wild type, neither exon 19 deletion nor exon 21 L858R was detected (and neither had undetermined status) and no other mutation (exons 18, 19, 20, and 21) was detected (and none had undetermined status); undetermined, exon 19 deletion or exon 21 L858R (or both) mutation status was undetermined; activating mutation not positive-other mutation positive, neither exon 19 deletion nor exon 21 L858R was detected (and neither had undetermined status), but another mutation (exon 18, 19, 20, or 21) was detected; and activating mutation not positive-other mutation status undetermined, neither exon 19 deletion nor exon 21 L858R was detected (and neither had undetermined status) and no other mutation (exon 18, 19, 20, or 21) was detected but the mutation status was undetermined for at least one."
  ],
  "groups": [
    {
      "name": "Erlotinib (ITT)",
      "n": 623,
      "type": "Intervention"
    },
    {
      "name": "Placebo (ITT)",
      "n": 350,
      "type": "Placebo"
    },
    {
      "name": "Total (ITT)",
      "n": 973,
      "type": "Total"
    },
    {
      "name": "Erlotinib (EGFRm+)",
      "n": 102,
      "type": "Intervention"
    },
    {
      "name": "Placebo (EGFRm+)",
      "n": 59,
      "type": "Placebo"
    },
    {
      "name": "Total (EGFRm+)",
      "n": 161,
      "type": "Total"
    }
  ],
  "characteristics": [
    {
      "original_label": "Sex, No. (%)",
      "standardized_name": "Sex",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Female Sex",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 257.0,
          "percentage": 41.3,
          "raw_string": "257 (41.3)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 141.0,
          "percentage": 40.3,
          "raw_string": "141 (40.3)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 398.0,
          "percentage": 40.9,
          "raw_string": "398 (40.9)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 64.7,
          "raw_string": "66 (64.7)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 66.1,
          "raw_string": "39 (66.1)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 105.0,
          "percentage": 65.2,
          "raw_string": "105 (65.2)"
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Male Sex",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 366.0,
          "percentage": 58.7,
          "raw_string": "366 (58.7)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 209.0,
          "percentage": 59.7,
          "raw_string": "209 (59.7)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 575.0,
          "percentage": 59.1,
          "raw_string": "575 (59.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 36.0,
          "percentage": 35.3,
          "raw_string": "36 (35.3)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 33.9,
          "raw_string": "20 (33.9)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 56.0,
          "percentage": 34.8,
          "raw_string": "56 (34.8)"
        }
      ]
    },
    {
      "original_label": "Age, years",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Mean (SD)",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "numeric_mean_sd",
          "mean": 62.0,
          "std_dev": 9.28,
          "raw_string": "62.0 (9.28)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "numeric_mean_sd",
          "mean": 61.8,
          "std_dev": 9.34,
          "raw_string": "61.8 (9.34)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "numeric_mean_sd",
          "mean": 61.9,
          "std_dev": 9.3,
          "raw_string": "61.9 (9.30)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "numeric_mean_sd",
          "mean": 60.3,
          "std_dev": 10.15,
          "raw_string": "60.3 (10.15)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "numeric_mean_sd",
          "mean": 60.4,
          "std_dev": 9.5,
          "raw_string": "60.4 (9.50)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "numeric_mean_sd",
          "mean": 60.3,
          "std_dev": 9.89,
          "raw_string": "60.3 (9.89)"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Median Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "raw_string": "62.0"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "raw_string": "62.0"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "raw_string": "62.0"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "raw_string": "62.0"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "numeric_median_iqr",
          "median": 60.0,
          "raw_string": "60.0"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "numeric_median_iqr",
          "median": 61.0,
          "raw_string": "61.0"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Age Range",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "numeric_mean_range",
          "range_min": 20.0,
          "range_max": 84.0,
          "raw_string": "20-84"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "numeric_mean_range",
          "range_min": 23.0,
          "range_max": 86.0,
          "raw_string": "23-86"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "numeric_mean_range",
          "range_min": 20.0,
          "range_max": 86.0,
          "raw_string": "20-86"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "numeric_mean_range",
          "range_min": 38.0,
          "range_max": 84.0,
          "raw_string": "38-84"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "numeric_mean_range",
          "range_min": 42.0,
          "range_max": 86.0,
          "raw_string": "42-86"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "numeric_mean_range",
          "range_min": 38.0,
          "range_max": 86.0,
          "raw_string": "38-86"
        }
      ]
    },
    {
      "original_label": "Race, No. (%)",
      "standardized_name": "Race",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "White Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 500.0,
          "percentage": 80.3,
          "raw_string": "500 (80.3)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 279.0,
          "percentage": 79.7,
          "raw_string": "279 (79.7)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 779.0,
          "percentage": 80.1,
          "raw_string": "779 (80.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 50.0,
          "raw_string": "51 (50.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 33.0,
          "percentage": 55.9,
          "raw_string": "33 (55.9)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 84.0,
          "percentage": 52.2,
          "raw_string": "84 (52.2)"
        }
      ]
    },
    {
      "original_label": "Black",
      "standardized_name": "Black Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 2.2,
          "raw_string": "14 (2.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 3.1,
          "raw_string": "11 (3.1)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 2.6,
          "raw_string": "25 (2.6)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "raw_string": "0"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.7,
          "raw_string": "1 (1.7)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.6,
          "raw_string": "1 (0.6)"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "Asian Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 107.0,
          "percentage": 17.2,
          "raw_string": "107 (17.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 60.0,
          "percentage": 17.1,
          "raw_string": "60 (17.1)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 167.0,
          "percentage": 17.2,
          "raw_string": "167 (17.2)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 50.0,
          "raw_string": "51 (50.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 42.4,
          "raw_string": "25 (42.4)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 76.0,
          "percentage": 47.2,
          "raw_string": "76 (47.2)"
        }
      ]
    },
    {
      "original_label": "Far East",
      "standardized_name": "Far East Asian",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Asian",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 89.0,
          "percentage": 14.3,
          "raw_string": "89 (14.3)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 48.0,
          "percentage": 13.7,
          "raw_string": "48 (13.7)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 137.0,
          "percentage": 14.1,
          "raw_string": "137 (14.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 40.0,
          "percentage": 39.2,
          "raw_string": "40 (39.2)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 32.2,
          "raw_string": "19 (32.2)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 59.0,
          "percentage": 36.6,
          "raw_string": "59 (36.6)"
        }
      ]
    },
    {
      "original_label": "Southeast Asia",
      "standardized_name": "Southeast Asian",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Asian",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 2.7,
          "raw_string": "17 (2.7)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 3.4,
          "raw_string": "12 (3.4)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 3.0,
          "raw_string": "29 (3.0)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 10.8,
          "raw_string": "11 (10.8)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 10.2,
          "raw_string": "6 (10.2)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 10.6,
          "raw_string": "17 (10.6)"
        }
      ]
    },
    {
      "original_label": "Indian subcontinent",
      "standardized_name": "Indian Subcontinent",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Asian",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 (0.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.1,
          "raw_string": "1 (0.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "American Indian/Alaska Native",
      "standardized_name": "American Indian/Alaska Native Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 (0.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.1,
          "raw_string": "1 (0.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other Race",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 (0.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.1,
          "raw_string": "1 (0.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "ECOG performance status, No. (%)",
      "standardized_name": "ECOG Performance Status",
      "category": "Baseline Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status 0",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 385.0,
          "percentage": 61.8,
          "raw_string": "385 (61.8)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 211.0,
          "percentage": 60.3,
          "raw_string": "211 (60.3)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 596.0,
          "percentage": 61.3,
          "raw_string": "596 (61.3)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 59.8,
          "raw_string": "61 (59.8)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 38.0,
          "percentage": 64.4,
          "raw_string": "38 (64.4)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 99.0,
          "percentage": 61.5,
          "raw_string": "99 (61.5)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status 1",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 230.0,
          "percentage": 36.9,
          "raw_string": "230 (36.9)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 134.0,
          "percentage": 38.3,
          "raw_string": "134 (38.3)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 364.0,
          "percentage": 37.4,
          "raw_string": "364 (37.4)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 40.0,
          "percentage": 39.2,
          "raw_string": "40 (39.2)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 35.6,
          "raw_string": "21 (35.6)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 37.9,
          "raw_string": "61 (37.9)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status 2",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 1.0,
          "raw_string": "6 (1.0)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 1.4,
          "raw_string": "5 (1.4)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 1.1,
          "raw_string": "11 (1.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.0,
          "raw_string": "1 (1.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.6,
          "raw_string": "1 (0.6)"
        }
      ]
    },
    {
      "original_label": "Not done",
      "standardized_name": "ECOG Performance Status Not Done",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.3,
          "raw_string": "2 (0.3)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.2,
          "raw_string": "2 (0.2)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Cigarette smoking history, No. (%)",
      "standardized_name": "Smoking History",
      "category": "Baseline Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Never smoked or ≤ 100 cigarettes in lifetime",
      "standardized_name": "Never Smoker",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Cigarette smoking history, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 129.0,
          "percentage": 20.7,
          "raw_string": "129 (20.7)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 70.0,
          "percentage": 20.0,
          "raw_string": "70 (20.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 199.0,
          "percentage": 20.5,
          "raw_string": "199 (20.5)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 64.7,
          "raw_string": "66 (64.7)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 35.0,
          "percentage": 59.3,
          "raw_string": "35 (59.3)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 101.0,
          "percentage": 62.7,
          "raw_string": "101 (62.7)"
        }
      ]
    },
    {
      "original_label": "Former smoker",
      "standardized_name": "Former Smoker",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Cigarette smoking history, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 423.0,
          "percentage": 67.9,
          "raw_string": "423 (67.9)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 240.0,
          "percentage": 68.6,
          "raw_string": "240 (68.6)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 663.0,
          "percentage": 68.1,
          "raw_string": "663 (68.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 36.0,
          "percentage": 35.3,
          "raw_string": "36 (35.3)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 33.9,
          "raw_string": "20 (33.9)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 56.0,
          "percentage": 34.8,
          "raw_string": "56 (34.8)"
        }
      ]
    },
    {
      "original_label": "Current smoker",
      "standardized_name": "Current Smoker",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Cigarette smoking history, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 71.0,
          "percentage": 11.4,
          "raw_string": "71 (11.4)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 40.0,
          "percentage": 11.4,
          "raw_string": "40 (11.4)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 111.0,
          "percentage": 11.4,
          "raw_string": "111 (11.4)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 6.8,
          "raw_string": "4 (6.8)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 2.5,
          "raw_string": "4 (2.5)"
        }
      ]
    },
    {
      "original_label": "Region, No. (%)",
      "standardized_name": "Geographic Region",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Asia Pacific",
      "standardized_name": "Asia Pacific",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 107.0,
          "percentage": 17.2,
          "raw_string": "107 (17.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 58.0,
          "percentage": 16.6,
          "raw_string": "58 (16.6)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 165.0,
          "percentage": 17.0,
          "raw_string": "165 (17.0)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 46.0,
          "percentage": 45.1,
          "raw_string": "46 (45.1)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 22.0,
          "percentage": 37.3,
          "raw_string": "22 (37.3)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 68.0,
          "percentage": 42.2,
          "raw_string": "68 (42.2)"
        }
      ]
    },
    {
      "original_label": "Western Europe*",
      "standardized_name": "Western Europe",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 167.0,
          "percentage": 26.8,
          "raw_string": "167 (26.8)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 89.0,
          "percentage": 25.4,
          "raw_string": "89 (25.4)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 256.0,
          "percentage": 26.3,
          "raw_string": "256 (26.3)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 11.8,
          "raw_string": "12 (11.8)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 16.9,
          "raw_string": "10 (16.9)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 22.0,
          "percentage": 13.7,
          "raw_string": "22 (13.7)"
        }
      ]
    },
    {
      "original_label": "Eastern Europe†",
      "standardized_name": "Eastern Europe",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 151.0,
          "percentage": 24.2,
          "raw_string": "151 (24.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 96.0,
          "percentage": 27.4,
          "raw_string": "96 (27.4)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 247.0,
          "percentage": 25.4,
          "raw_string": "247 (25.4)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 17.6,
          "raw_string": "18 (17.6)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 20.3,
          "raw_string": "12 (20.3)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 18.6,
          "raw_string": "30 (18.6)"
        }
      ]
    },
    {
      "original_label": "Latin America",
      "standardized_name": "Latin America",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 1.0,
          "raw_string": "6 (1.0)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.6,
          "raw_string": "2 (0.6)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 0.8,
          "raw_string": "8 (0.8)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.0,
          "raw_string": "1 (1.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.6,
          "raw_string": "1 (0.6)"
        }
      ]
    },
    {
      "original_label": "North America",
      "standardized_name": "North America",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 192.0,
          "percentage": 30.8,
          "raw_string": "192 (30.8)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 105.0,
          "percentage": 30.0,
          "raw_string": "105 (30.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 297.0,
          "percentage": 30.5,
          "raw_string": "297 (30.5)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 24.5,
          "raw_string": "25 (24.5)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 15.0,
          "percentage": 25.4,
          "raw_string": "15 (25.4)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 40.0,
          "percentage": 24.8,
          "raw_string": "40 (24.8)"
        }
      ]
    },
    {
      "original_label": "Histology, No. (%)",
      "standardized_name": "Tumor Histology",
      "category": "Baseline Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Adenocarcinoma",
      "standardized_name": "Adenocarcinoma",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 367.0,
          "percentage": 58.9,
          "raw_string": "367 (58.9)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 211.0,
          "percentage": 60.3,
          "raw_string": "211 (60.3)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 578.0,
          "percentage": 59.4,
          "raw_string": "578 (59.4)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 91.0,
          "percentage": 89.2,
          "raw_string": "91 (89.2)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 55.0,
          "percentage": 93.2,
          "raw_string": "55 (93.2)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 146.0,
          "percentage": 90.7,
          "raw_string": "146 (90.7)"
        }
      ]
    },
    {
      "original_label": "Squamous cell carcinoma",
      "standardized_name": "Squamous Cell Carcinoma",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 196.0,
          "percentage": 31.5,
          "raw_string": "196 (31.5)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 111.0,
          "percentage": 31.7,
          "raw_string": "111 (31.7)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 307.0,
          "percentage": 31.6,
          "raw_string": "307 (31.6)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 6.9,
          "raw_string": "7 (6.9)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 5.1,
          "raw_string": "3 (5.1)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 6.2,
          "raw_string": "10 (6.2)"
        }
      ]
    },
    {
      "original_label": "Undifferentiated large cell",
      "standardized_name": "Undifferentiated Large Cell Carcinoma",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 22.0,
          "percentage": 3.5,
          "raw_string": "22 (3.5)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 2.3,
          "raw_string": "8 (2.3)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 3.1,
          "raw_string": "30 (3.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Mixed NSCLC",
      "standardized_name": "Mixed NSCLC",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 4.7,
          "raw_string": "29 (4.7)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 5.1,
          "raw_string": "18 (5.1)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 47.0,
          "percentage": 4.8,
          "raw_string": "47 (4.8)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 3.9,
          "raw_string": "4 (3.9)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.7,
          "raw_string": "1 (1.7)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.1,
          "raw_string": "5 (3.1)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other Histology",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 1.4,
          "raw_string": "9 (1.4)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.6,
          "raw_string": "2 (0.6)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 1.1,
          "raw_string": "11 (1.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Extent of disease at diagnosis, No. (%)",
      "standardized_name": "Disease Stage at Diagnosis",
      "category": "Baseline Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Stage IA",
      "standardized_name": "Stage IA",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Extent of disease at diagnosis, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 (0.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.6,
          "raw_string": "2 (0.6)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.3,
          "raw_string": "3 (0.3)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.0,
          "raw_string": "1 (1.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.7,
          "raw_string": "1 (1.7)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.2,
          "raw_string": "2 (1.2)"
        }
      ]
    },
    {
      "original_label": "Stage IB",
      "standardized_name": "Stage IB",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Extent of disease at diagnosis, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 329.0,
          "percentage": 52.8,
          "raw_string": "329 (52.8)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 167.0,
          "percentage": 47.7,
          "raw_string": "167 (47.7)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 496.0,
          "percentage": 51.0,
          "raw_string": "496 (51.0)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 52.0,
          "percentage": 51.0,
          "raw_string": "52 (51.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 23.0,
          "percentage": 39.0,
          "raw_string": "23 (39.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 75.0,
          "percentage": 46.6,
          "raw_string": "75 (46.6)"
        }
      ]
    },
    {
      "original_label": "Stage IIA",
      "standardized_name": "Stage IIA",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Extent of disease at diagnosis, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 42.0,
          "percentage": 6.7,
          "raw_string": "42 (6.7)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 24.0,
          "percentage": 6.9,
          "raw_string": "24 (6.9)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 6.8,
          "raw_string": "66 (6.8)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 8.8,
          "raw_string": "9 (8.8)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 5.6,
          "raw_string": "9 (5.6)"
        }
      ]
    },
    {
      "original_label": "Stage IIB",
      "standardized_name": "Stage IIB",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Extent of disease at diagnosis, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 155.0,
          "percentage": 24.9,
          "raw_string": "155 (24.9)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 99.0,
          "percentage": 28.3,
          "raw_string": "99 (28.3)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 254.0,
          "percentage": 26.1,
          "raw_string": "254 (26.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 20.6,
          "raw_string": "21 (20.6)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 28.8,
          "raw_string": "17 (28.8)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 38.0,
          "percentage": 23.6,
          "raw_string": "38 (23.6)"
        }
      ]
    },
    {
      "original_label": "Stage IIIA",
      "standardized_name": "Stage IIIA",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Extent of disease at diagnosis, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 93.0,
          "percentage": 14.9,
          "raw_string": "93 (14.9)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 58.0,
          "percentage": 16.6,
          "raw_string": "58 (16.6)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 151.0,
          "percentage": 15.5,
          "raw_string": "151 (15.5)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 17.6,
          "raw_string": "18 (17.6)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 30.5,
          "raw_string": "18 (30.5)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 36.0,
          "percentage": 22.4,
          "raw_string": "36 (22.4)"
        }
      ]
    },
    {
      "original_label": "Stage IIIB",
      "standardized_name": "Stage IIIB",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Extent of disease at diagnosis, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.3,
          "raw_string": "2 (0.3)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.2,
          "raw_string": "2 (0.2)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Stage IV",
      "standardized_name": "Stage IV",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Extent of disease at diagnosis, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.2,
          "raw_string": "1 (0.2)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.1,
          "raw_string": "1 (0.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.0,
          "raw_string": "1 (1.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.6,
          "raw_string": "1 (0.6)"
        }
      ]
    },
    {
      "original_label": "Primary surgical procedure, No. (%)",
      "standardized_name": "Primary Surgical Procedure",
      "category": "Treatment Information",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Pneumonectomy",
      "standardized_name": "Pneumonectomy",
      "category": "Treatment Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary surgical procedure, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 83.0,
          "percentage": 13.3,
          "raw_string": "83 (13.3)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 38.0,
          "percentage": 10.9,
          "raw_string": "38 (10.9)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 121.0,
          "percentage": 12.4,
          "raw_string": "121 (12.4)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 7.8,
          "raw_string": "8 (7.8)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.7,
          "raw_string": "1 (1.7)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 5.6,
          "raw_string": "9 (5.6)"
        }
      ]
    },
    {
      "original_label": "Lobectomy",
      "standardized_name": "Lobectomy",
      "category": "Treatment Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary surgical procedure, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 491.0,
          "percentage": 78.8,
          "raw_string": "491 (78.8)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 286.0,
          "percentage": 81.7,
          "raw_string": "286 (81.7)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 777.0,
          "percentage": 79.9,
          "raw_string": "777 (79.9)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 86.0,
          "percentage": 84.3,
          "raw_string": "86 (84.3)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 57.0,
          "percentage": 96.6,
          "raw_string": "57 (96.6)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 143.0,
          "percentage": 88.8,
          "raw_string": "143 (88.8)"
        }
      ]
    },
    {
      "original_label": "Bilobectomy",
      "standardized_name": "Bilobectomy",
      "category": "Treatment Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary surgical procedure, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 6.6,
          "raw_string": "41 (6.6)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 5.7,
          "raw_string": "20 (5.7)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 6.3,
          "raw_string": "61 (6.3)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 7.8,
          "raw_string": "8 (7.8)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.7,
          "raw_string": "1 (1.7)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 5.6,
          "raw_string": "9 (5.6)"
        }
      ]
    },
    {
      "original_label": "Sleeve lobectomy",
      "standardized_name": "Sleeve Lobectomy",
      "category": "Treatment Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary surgical procedure, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 1.0,
          "raw_string": "6 (1.0)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.9,
          "raw_string": "3 (0.9)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 0.9,
          "raw_string": "9 (0.9)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other Surgical Procedure",
      "category": "Treatment Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary surgical procedure, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.3,
          "raw_string": "2 (0.3)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.9,
          "raw_string": "3 (0.9)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 0.5,
          "raw_string": "5 (0.5)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Adjuvant chemotherapy, No. (%)",
      "standardized_name": "Adjuvant Chemotherapy",
      "category": "Treatment Information",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Received Adjuvant Chemotherapy",
      "category": "Treatment Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Adjuvant chemotherapy, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 315.0,
          "percentage": 50.6,
          "raw_string": "315 (50.6)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 200.0,
          "percentage": 57.1,
          "raw_string": "200 (57.1)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 515.0,
          "percentage": 52.9,
          "raw_string": "515 (52.9)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 46.0,
          "percentage": 45.1,
          "raw_string": "46 (45.1)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 33.0,
          "percentage": 55.9,
          "raw_string": "33 (55.9)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 79.0,
          "percentage": 49.1,
          "raw_string": "79 (49.1)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Did Not Receive Adjuvant Chemotherapy",
      "category": "Treatment Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Adjuvant chemotherapy, No. (%)",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 308.0,
          "percentage": 49.4,
          "raw_string": "308 (49.4)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 150.0,
          "percentage": 42.9,
          "raw_string": "150 (42.9)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 458.0,
          "percentage": 47.1,
          "raw_string": "458 (47.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 56.0,
          "percentage": 54.9,
          "raw_string": "56 (54.9)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 26.0,
          "percentage": 44.1,
          "raw_string": "26 (44.1)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 82.0,
          "percentage": 50.9,
          "raw_string": "82 (50.9)"
        }
      ]
    },
    {
      "original_label": "EGFR mutation status, No. (%)‡",
      "standardized_name": "EGFR Mutation Status",
      "category": "Biomarker Information",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Activating mutation positive",
      "standardized_name": "Activating EGFR Mutation Positive",
      "category": "Biomarker Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation status, No. (%)‡",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 102.0,
          "percentage": 16.4,
          "raw_string": "102 (16.4)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 59.0,
          "percentage": 16.9,
          "raw_string": "59 (16.9)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 161.0,
          "percentage": 16.5,
          "raw_string": "161 (16.5)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 102.0,
          "percentage": 100.0,
          "raw_string": "102 (100.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 59.0,
          "percentage": 100.0,
          "raw_string": "59 (100.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 161.0,
          "percentage": 100.0,
          "raw_string": "161 (100.0)"
        }
      ]
    },
    {
      "original_label": "Wild type",
      "standardized_name": "EGFR Wild Type",
      "category": "Biomarker Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation status, No. (%)‡",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 458.0,
          "percentage": 73.5,
          "raw_string": "458 (73.5)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 245.0,
          "percentage": 70.0,
          "raw_string": "245 (70.0)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 703.0,
          "percentage": 72.3,
          "raw_string": "703 (72.3)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Undetermined",
      "standardized_name": "EGFR Mutation Status Undetermined",
      "category": "Biomarker Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation status, No. (%)‡",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 4.7,
          "raw_string": "29 (4.7)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 4.6,
          "raw_string": "16 (4.6)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 45.0,
          "percentage": 4.6,
          "raw_string": "45 (4.6)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Activating mutation not positive",
      "standardized_name": "Activating EGFR Mutation Not Positive",
      "category": "Biomarker Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation status, No. (%)‡",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 4.8,
          "raw_string": "30 (4.8)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 7.7,
          "raw_string": "27 (7.7)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 57.0,
          "percentage": 5.9,
          "raw_string": "57 (5.9)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Other mutation positive",
      "standardized_name": "Other EGFR Mutation Positive",
      "category": "Biomarker Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Activating mutation not positive",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 3.0,
          "raw_string": "19 (3.0)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 18.0,
          "percentage": 5.1,
          "raw_string": "18 (5.1)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 37.0,
          "percentage": 3.8,
          "raw_string": "37 (3.8)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Other mutation status undetermined",
      "standardized_name": "Other EGFR Mutation Status Undetermined",
      "category": "Biomarker Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Activating mutation not positive",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 1.8,
          "raw_string": "11 (1.8)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 2.6,
          "raw_string": "9 (2.6)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 2.1,
          "raw_string": "20 (2.1)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Data not available",
      "standardized_name": "EGFR Mutation Status Data Not Available",
      "category": "Biomarker Information",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation status, No. (%)‡",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 0.6,
          "raw_string": "4 (0.6)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.9,
          "raw_string": "3 (0.9)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 0.7,
          "raw_string": "7 (0.7)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)"
        }
      ]
    },
    {
      "original_label": "Tumor size, mm",
      "standardized_name": "Tumor Size",
      "unit": "mm",
      "category": "Baseline Characteristics",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Mean (SD)",
      "standardized_name": "Tumor Size",
      "unit": "mm",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor size, mm",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "numeric_mean_sd",
          "mean": 42.94,
          "std_dev": 22.794,
          "raw_string": "42.94 (22.794)"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "numeric_mean_sd",
          "mean": 40.36,
          "std_dev": 20.235,
          "raw_string": "40.36 (20.235)"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "numeric_mean_sd",
          "mean": 42.01,
          "std_dev": 21.931,
          "raw_string": "42.01 (21.931)"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "numeric_mean_sd",
          "mean": 36.19,
          "std_dev": 16.034,
          "raw_string": "36.19 (16.034)"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "numeric_mean_sd",
          "mean": 32.86,
          "std_dev": 11.701,
          "raw_string": "32.86 (11.701)"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "numeric_mean_sd",
          "mean": 34.97,
          "std_dev": 14.646,
          "raw_string": "34.97 (14.646)"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Median Tumor Size",
      "unit": "mm",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor size, mm",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "numeric_median_iqr",
          "median": 38.0,
          "raw_string": "38.00"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "numeric_median_iqr",
          "median": 35.0,
          "raw_string": "35.00"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "numeric_median_iqr",
          "median": 37.0,
          "raw_string": "37.00"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "numeric_median_iqr",
          "median": 32.0,
          "raw_string": "32.00"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "numeric_median_iqr",
          "median": 33.0,
          "raw_string": "33.00"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "numeric_median_iqr",
          "median": 32.0,
          "raw_string": "32.00"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Tumor Size Range",
      "unit": "mm",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor size, mm",
      "group_data": [
        {
          "group_name": "Erlotinib (ITT)",
          "data_type": "numeric_mean_range",
          "range_min": 9.0,
          "range_max": 180.0,
          "raw_string": "9.0-180.0"
        },
        {
          "group_name": "Placebo (ITT)",
          "data_type": "numeric_mean_range",
          "range_min": 10.0,
          "range_max": 140.0,
          "raw_string": "10.0-140.0"
        },
        {
          "group_name": "Total (ITT)",
          "data_type": "numeric_mean_range",
          "range_min": 9.0,
          "range_max": 180.0,
          "raw_string": "9.0-180.0"
        },
        {
          "group_name": "Erlotinib (EGFRm+)",
          "data_type": "numeric_mean_range",
          "range_min": 13.0,
          "range_max": 90.0,
          "raw_string": "13.0-90.0"
        },
        {
          "group_name": "Placebo (EGFRm+)",
          "data_type": "numeric_mean_range",
          "range_min": 10.0,
          "range_max": 70.0,
          "raw_string": "10.0-70.0"
        },
        {
          "group_name": "Total (EGFRm+)",
          "data_type": "numeric_mean_range",
          "range_min": 10.0,
          "range_max": 90.0,
          "raw_string": "10.0-90.0"
        }
      ]
    }
  ]
}